Telomere Length Alterations Associated with Breast, Thyroid and Cervical Cancers


Affiliations

  • Khalsa College, Department of Zoology, Amritsar, Punjab, 143001
  • Khalsa College, Department of Zoology, Amritsar, Punjab, 143001, India

Abstract

Telomeres are specialised structures of eukaryotic chromosomes that are present at each end of chromosomes. Telomeric length acts as a biological clock which helps to determine the life span of a cell and an organism. Telomeric shortening is also associated with various disease patterns including Dyskeratosis Congenita, Parkinson’s disease, Ulcerative Colitis and chronic hepatitis. Any anomality in the telomeric function initiates genomic instability which increases the risk of cancer. Individuals with short telomeres are at increased risk for cancer. This review paper aims to find out the studies pointing out the relation of telomeric length and different types of cancers including breast, thyroid and cervical cancer. A positive correlation has been found in between telomeric shortening and cancer occurrence. Further studies are suggested to strengthen the association of telomere length alterations with specific cancer type.

Keywords

Biomarker, Breast Cancer, Cervical Cancer, Telomere, Telomeric Shortening, Telomerase, Thyroid Cancer

Full Text:

References

Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer. 2015; 112:313–8. DOI: bjc2014561 [pii];10.1038/bjc.2014.561

Augustine T, Maitra R, Goel S. Telomere length regulation through epidermal growth factor receptor signaling in cancer. Genes Cancer. 2017; 8:550–8. DOI: 10.18632/genesandcancer.140 [doi];140 [pii] https://doi.org/10.18632/genesandcancer.140

Biegler KA, Anderson AK, Wenzel LB, Osann K, Nelson EL. Longitudinal change in telomere length and the chronic stress response in a randomized pilot biobehavioral clinical study: Implications for cancer prevention. Cancer Prev Res (Phila). 2012; 5:1173–82. DOI: 1940-6207.CAPR-12-0008 [pii];10.1158/1940-6207.CAPR-12-0008

Frescas D, de LT. A TIN2 dyskeratosis congenita mutation causes telomerase-independent telomere shortening in mice. Genes Dev. 2014; 28:153–66. DOI: 28/2/153 [pii];10.1101/gad.233395.113

Lee JW. Telomere shortening by mutations in the RTEL1 helicase cause severe form of dyskeratosis congenita, HoyerallHreidarsson syndrome. Clin Genet. 2013; 84:210. DOI: 10.1111/cge.12175 [doi] https://doi.org/10.1111/cge.12175

Friis-Ottessen M, Bendix L, Kolvraa S, Norheim-Andersen S, De Angelis PM, Clausen OP. Telomere shortening correlates to dysplasia but not to DNA aneuploidy in longstanding ulcerative colitis. BMC Gastroenterol. 2014; 14:8. DOI: 1471-230X-14-8 [pii];10.1186/1471-230X-14-8

Piciocchi M, Cardin R, Cillo U, Vitale A, Cappon A, Mescoli C, Guido M, Rugge M, Burra P, Floreani A, Farinati F. Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. Transl Res. 2016; 168:122–33. DOI: S19315244(15)00298-4 [pii];10.1016/j.trsl.2015.08.012

Cordoba-Lanus E, Cazorla-Rivero S, Espinoza-Jimenez A, de-Torres JP, Pajares MJ, Aguirre-Jaime A, Celli B, Casanova C. Erratum to Telomere shortening and accelerated aging in COPD: Findings from the BODE cohort. Respir Res. 2017; 18:113. DOI: 10.1186/s12931-017-0589-7 [doi];10.1186/ s12931-017-0589-7 [pii] https://doi.org/10.1186/s12931017-0589-7

Cordoba-Lanus E, Cazorla-Rivero S, Espinoza-Jimenez A, de-Torres JP, Pajares MJ, Aguirre-Jaime A, Celli B, Casanova C. Telomere shortening and accelerated aging in COPD: Findings from the BODE cohort. Respir Res. 2017; 18:59. DOI: 10.1186/s12931-017-0547-4 [doi];10.1186/ s12931-017-0547-4 [pii] https://doi.org/10.1186/s12931017-0547-4

Liu Z, Zhang J, Yan J, Wang Y, Li Y. Leucocyte telomere shortening in relation to newly diagnosed type 2 diabetic patients with depression. Oxid Med Cell Longev. 2014; 2014:673959. DOI: 10.1155/2014/673959 [doi] https://doi.org/10.1155/2014/673959

Ping F, Li ZY, Lv K, Zhou MC, Dong YX, Sun Q, Li YX.Deoxyribonucleic acid telomere length shortening can predict the incidence of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Diabetes Investig. 2017; 8:174–80. DOI: 10.1111/jdi.12555 https://doi.org/10.1111/jdi.12555

Tajbakhsh S, Aliakbari K, Hussey DJ, Lower KM, Donato AJ, Sokoya EM. Differential telomere shortening in blood versus arteries in an animal model of type 2 diabetes. J Diabetes Res. 2015; 2015:153829. DOI: 10.1155/2015/153829 https:// doi.org/10.1155/2015/153829

Hammadah M, Al M, I, Wilmot K, Ramadan R, Abdelhadi N, Alkhoder A, Obideen M, Pimple PM, Levantsevych O, Kelli HM, Shah A, Sun YV, Pearce B, Kutner M, Long Q, Ward L, Ko YA, Hosny MK, Lin J, Zhao J, Bremner JD, Kim J, Waller EK, Raggi P, Sheps D, Quyyumi AA, Vaccarino V. Telomere shortening, regenerative capacity, and cardiovascular outcomes. Circ Res. 2017; 120:1130– 8. DOI: CIRCRESAHA.116.309421 [pii];10.1161/CIRCRESAHA.116.309421

Baragetti A, Palmen J, Garlaschelli K, Grigore L, Pellegatta F, Tragni E, Catapano AL, Humphries SE, Norata GD, Talmud PJ. Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population.J Intern Med. 2015; 277:478–87. DOI: 10.1111/joim.12282 https://doi.org/10.1111/joim.12282

Chang AC, Ong SG, LaGory EL, Kraft PE, Giaccia AJ, Wu JC, Blau HM. Telomere shortening and metabolic compromise underlie dystrophic cardiomyopathy. Proc Natl Acad Sci USA. 2016; 113:13120–5. DOI: 1615340113 [pii];10.1073/pnas.1615340113

Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease.Nat Rev Cardiol. 2013; 10:274–83. DOI: nrcardio.2013.30 [pii];10.1038/nrcardio.2013.30

Guzzardi MA, Iozzo P, Salonen M, Kajantie E, Eriksson JG. Rate of telomere shortening and metabolic and cardiovascular risk factors: A longitudinal study in the 1934-44 Helsinki Birth Cohort Study. Ann Med. 2015; 47:499–505.DOI: 10.3109/07853890.2015.1074718 https://doi.org/10.3 109/07853890.2015.1074718

Jenkins EC, Marchi EJ, Velinov MT, Ye L, Krinsky-McHale SJ, Zigman WB, Schupf N, Silverman WP. Longitudinal telomere shortening and early Alzheimer’s disease progression in adults with down syndrome. Am J Med GenetB Neuropsychiatr Genet. 2017; 174:772–8. DOI: 10.1002/ ajmg.b.32575 https://doi.org/10.1002/ajmg.b.32575

Boccardi V, Pelini L, Ercolani S, Ruggiero C, Mecocci P. From cellular senescence to Alzheimer’s disease: The role of telomere shortening. Ageing Res Rev. 2015; 22:1–8. DOI: S1568-1637(15)00037-9 [pii];10.1016/j.arr.2015.04.003

Cai Z, Yan LJ, Ratka A. Telomere shortening and Alzheimer’s disease. Neuromolecular Med. 2013; 15:25–48.DOI: 10.1007/s12017-012-8207-9 https://doi.org/10.1007/ s12017-012-8207-9

Liu M, Huo YR, Wang J, Wang C, Liu S, Liu S, Wang J, Ji Y.Telomere shortening in Alzheimer’s disease patients. Ann Clin Lab Sci. 2016; 46:260-26–5. DOI: 46/3/260 [pii]

Zhan Y, Song C, Karlsson R, Tillander A, Reynolds CA, Pedersen NL, Hagg S. Telomere length shortening and Alzheimer disease - A mendelian randomization study. JAMA Neurol. 2015; 72:1202–3. DOI: 2452064 [pii];10.1001/jamaneurol.2015.1513

Sugishita Y, Kammori M, Yamada O, Poon SS, Kobayashi M, Onoda N, Yamazaki K, Fukumori T, Yoshikawa K, Onose H, Ishii S, Yamada E, Yamada T. Amplification of the human epidermal growth factor receptor 2 gene in differentiated thyroid cancer correlates with telomere shortening.Int J Oncol. 2013; 42:1589–96. DOI: 10.3892/ijo.2013.1848 https://doi.org/10.3892/ijo.2013.1848

Aviv A, Anderson JJ, Shay JW, Mutations, cancer and the telomere length paradox. Trends Cancer. 2017; 3:253–8. DOI: S2405-8033(17)30043-2 [pii];10.1016/j. trecan.2017.02.005

Finot F, Kaddour A, Morat L, Mouche I, Zaguia N, Cuceu C, Souverville D, Negrault S, Cariou O, Essahli A, Prigent N, Saul J, Paillard F, Heidingsfelder L, Lafouge P, Al JM, Hempel WM, El MM, Colicchio B, Dieterlen A, Jeandidier E, Sabatier L, Clements J, M’Kacher R. Genotoxic risk of ethyl-paraben could be related to telomere shortening. J Appl Toxicol. 2017; 37:758–71. DOI: 10.1002/jat.3425 https://doi.org/10.1002/jat.3425

Samulin EJ, Noto HO, Skare O, Lie JS, Petersen-Overleir M, Reszka E, Peplonska B, Zienolddiny S. Mechanisms of breast cancer risk in shift workers: association of telomere shortening with the duration and intensity of night work.Cancer Med. 2017; 6:1988–97. DOI: 10.1002/cam4.1135 https://doi.org/10.1002/cam4.1135

Kammori M, Sugishita Y, Okamoto T, Kobayashi M, Yamazaki K, Yamada E, Yamada T. Telomere shortening in breast cancer correlates with the pathological features of tumor progression. Oncol Rep. 2015; 34:627–32. DOI: 10.3892/or.2015.4063 https://doi.org/10.3892/or.2015.4063

Murillo-Ortiz B, Martinez-Garza S, Suarez GD, Castillo Valenzuela RD, Garcia Regalado JF, Cano VG. Association between telomere length and CYP19 TTTA repetition polymorphism in healthy and breast cáncer diagnosed women. Breast Cancer (Dove Med Press). 2017; 9:21–7. DOI: 10.2147/BCTT.S125431 [doi];bctt-9-021 [pii] https:// doi.org/10.2147/BCTT.S125431

Kaya Z, Akkiprik M, Karabulut S, Peker I, Gullu AG, Ozmen T, Gulluoglu BM, Kaya H, Ozer A. Comparison of telomere length and insulin-like growth factor-binding protein 7 promoter methylation between breast cancer tissues and adjacent normal tissues in Turkish women. J Clin Lab Anal. 2017; 31. DOI: 10.1002/jcla.22083 https://doi.org/10.1002/jcla.22083

Reddy V, Wu M, Ciavattone N, McKenty N, Menon M, Barrack ER, Reddy GP, Kim SH. ATM inhibition potentiates death of androgen receptor-inactivated prostate cancer cells with telomere dysfunction. J Biol Chem.2015; 290:25522–33. DOI: M115.671404 [pii];10.1074/jbc.M115.671404

Renault AL, Mebirouk N, Cavaciuti E, Le GD, Lecarpentier J, d’Enghien CD, Lauge A, Dondon MG, Labbe M, Lesca G, Leroux D, Gladieff L, Adenis C, Faivre L, GilbertDussardier B, Lortholary A, Fricker JP, Dahan K, Bay JO, Longy M, Buecher B, Janin N, Zattara H, Berthet P, Combes A, Coupier I, Hall J, Stoppa-Lyonnet D, Andrieu N, Lesueur F. Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families. Carcinogenesis. 2017; 38:994–1003. DOI: 3994029 [pii];10.1093/carcin/bgx074

Zhou S, Xiao Y, Zhuang Y, Liu Y, Zhao H, Yang H, Xie C, Zhou F, Zhou Y. Knockdown of homeobox containing 1 increases the radiosensitivity of cervical cancer cells through telomere shortening. Oncol Rep. 2017; 38:515– 21. DOI: 10.3892/or.2017.5707 https://doi.org/10.3892/ or.2017.5707

Natarajan S, Begum F, Gim J, Wark L, Henderson D, Davie JR, Hombach-Klonisch S, Klonisch T. High mobility groupA2 protects cancer cells against telomere dysfunction.Oncotarget. 2016; 7:12761–82. DOI: 6938 [pii];10.18632/ oncotarget.6938

Ke S, Zhou F, Yang H, Wei Y, Gong J, Mei Z, Wu L, Yu H, Zhou Y. Downregulation of high mobility group box 1 modulates telomere homeostasis and increases the radiosensitivity of human breast cancer cells. Int J Oncol.2015; 46:1051–8. DOI: 10.3892/ijo.2014.2793 https://doi. org/10.3892/ijo.2014.2793

Cantara S, Pisu M, Frau DV, Caria P, Dettori T, Capezzone M, Capuano S, Vanni R, Pacini F. Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer. J Clin Endocrinol Metab. 2012; 97:E1327–31. DOI: jc.2011-2096 [pii];10.1210/jc.2011-2096

Gramatges MM, Liu Q, Yasui Y, Okcu MF, Neglia JP, Strong LC, Armstrong GT, Robison LL, Bhatia S. Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Clin Cancer Res. 2014; 20:904–11. DOI: 1078-0432.CCR-13-2076 [pii];10.1158/1078-0432.CCR13-2076

He M, Bian B, Gesuwan K, Gulati N, Zhang L, Nilubol N, Kebebew E. Telomere length is shorter in affected members of families with familial nonmedullary thyroid cancer. Thyroid. 2013; 23:301–7. DOI: 10.1089/thy.2012.0270 https://doi.org/10.1089/thy.2012.0270

Caria P, Cantara S, Frau DV, Pacini F, Vanni R, Dettori T: Genetic heterogeneity of HER2 amplification and telomere shortening in papillary thyroid carcinoma. Int J Mol Sci. 2016; 17. DOI: ijms17101759 [pii];10.3390/ijms17101759

Merghoub N, El BH, Benbacer L, Gmouh S, Trentesaux C, Brassart B, Attaleb M, Madoulet C, Wenner T, Amzazi S, Morjani H, El MM. Tomentosin induces telomere shortening and caspase-dependant apoptosis in cervical cancer cells. J Cell Biochem. 2017; 118:1689–98. DOI: 10.1002/jcb.25826 https://doi.org/10.1002/jcb.25826

Merghoub N, El BH, Benbacer L, Gmouh S, Trentesaux C, Brassart B, Terryn C, Attaleb M, Madoulet C, Benjouad A, Amzazi S, El MM, Morjani H. Inula viscosa extracts induces telomere shortening and apoptosis in cancer cells and overcome drug resistance. Nutr Cancer. 2016; 68:131– 43. DOI: 10.1080/01635581.2016.1115105 https://doi.org/1 0.1080/01635581.2016.1115105

Zhou S, Xiao Y, Zhuang Y, Liu Y, Zhao H, Yang H, Xie C, Zhou F, Zhou Y. Knockdown of homeobox containing 1 increases the radiosensitivity of cervical cancer cells through telomere shortening. Oncol Rep. 2017; 38:515– 21. DOI: 10.3892/or.2017.5707 https://doi.org/10.3892/ or.2017.5707

Samulin EJ, Noto HO, Skare O, Lie JS, Petersen-Overleir M, Reszka E, Peplonska B, Zienolddiny S. Mechanisms of breast cancer risk in shift workers: A.ssociation of telomere shortening with the duration and intensity of night work.Cancer Med 2017; 6:1988–97. DOI: 10.1002/cam4.1135 https://doi.org/10.1002/cam4.1135

Kammori M, Sugishita Y, Okamoto T, Kobayashi M, Yamazaki K, Yamada E, Yamada T. Telomere shortening in breast cancer correlates with the pathological features of tumor progression. Oncol Rep. 2015; 34:627–32. DOI: 10.3892/or.2015.4063 https://doi.org/10.3892/or.2015.4063

Cassar L, Nicholls C, Pinto AR, Chen R, Wang L, Li H, Liu JP. TGF-beta receptor mediated telomerase inhibition, telomere shortening and breast cancer cell senescence. Protein Cell. 2017; 8:39–54. DOI: 10.1007/s13238-016-03221;10.1007/s13238-016-0322-1 [pii] https://doi.org/10.1007/ s13238-016-0322-1


Refbacks

  • There are currently no refbacks.